黑料网

Skip to main content

Jiandong ZhangCongratulations to Jiandong Zhang, M.D., Interventional Cardiology Fellow, Division of Cardiology, Department of Medicine; Pharmacology alumnus postdoctoral fellow, formerly in the Jensen Lab, in collaboration with Joseph S. Rossi, MD, MSCI, FACC, FSCAI, Professor of Medicine; Director, Cardiac Catheterization Lab; Program Director, Interventional Cardiology Fellowship; Co-Director of Cardiology Clinical Trials, and , a 5th-year doctoral student in the Department of Epidemiology, 黑料网-Chapel Hill Gillings School of Global Public Health, for publishing articles, titled “Cardiomyocyte Alpha-1A Adrenergic Receptors Mitigate Postinfarct Remodeling and Mortality by Constraining Necroptosis” and “Cardiovascular Outcomes of Alpha Blockers vs 5-alpha Reductase Inhibitors for Benign Prostatic Hyperplasia”, in the journals and , respectively.

Brian JensenChase Latour, Ph.D.Joseph S. Rossi, M.D., MSCI, FACC, FSCADr. Zhang was a first author on both of these two recently published papers. The study that appears in JACC used cell culture and a mouse model of myocardial infarction (MI) to identify a novel mechanism of cardioprotection for alpha-1A adrenergic receptors. In collaboration with Dr. Rossi, they also found that patients taking medications that inhibit alpha-1 adrenergic receptors (鈥渁lpha blockers鈥) had an increased risk of death compared with patients not taking alpha-blockers after undergoing PCI for MI at 黑料网. The study that appears in JAMA Open was carried out in collaboration with trainees and faculty in the 黑料网 School of Public Health and the 黑料网 Department of Urology. Here Dr. Zhang and co-first author, Chase Latour, followed up on the 黑料网 single center data indicating cardiovascular risk associated with alpha blockers (as above) in a 20% random sample of Medicare beneficiaries. They found that men taking alpha blockers (n=163,829) had a modest but statistically significant increased risk of death and Major Adverse Cardiac Events within one year of starting treatment when compared with men who were prescribed 5-alpha reductase inhibitors (n=26,039), the second-most commonly used medication to treat BPH. Both of these papers can can be read online now.


黑料网 Cardiology